Compare KKR & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KKR | BMY |
|---|---|---|
| Founded | 1976 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.0B | 110.2B |
| IPO Year | 2010 | N/A |
| Metric | KKR | BMY |
|---|---|---|
| Price | $127.68 | $54.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $155.07 | $56.31 |
| AVG Volume (30 Days) | 3.9M | ★ 15.8M |
| Earning Date | 02-03-2026 | 02-05-2026 |
| Dividend Yield | 0.58% | ★ 4.67% |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.37 | ★ 2.97 |
| Revenue | $22,245,686,000.00 | ★ $48,034,000,000.00 |
| Revenue This Year | N/A | $0.27 |
| Revenue Next Year | $30.15 | N/A |
| P/E Ratio | $53.86 | ★ $18.16 |
| Revenue Growth | N/A | ★ 1.26 |
| 52 Week Low | $86.15 | $42.52 |
| 52 Week High | $170.40 | $63.33 |
| Indicator | KKR | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 63.78 |
| Support Level | $130.30 | $53.92 |
| Resistance Level | $130.82 | $55.04 |
| Average True Range (ATR) | 2.76 | 0.91 |
| MACD | -1.01 | -0.14 |
| Stochastic Oscillator | 0.63 | 78.15 |
KKR is one of the world's largest alternative asset managers, with $723.2 billion in total managed assets, including $585.0 billion in fee-earning AUM, at the end of September 2025. The company has two core segments: asset management (which includes private markets—private equity, credit, infrastructure, energy, and real estate—and public markets—primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.